The DOI matches its Crossref record.
An efficient and low immunostimulatory nanoparticle formulation for systemic siRNA delivery to the tumor
Open accessAbstract
We have developed a nanoparticle formulation [liposomes-protamine-hyaluronic acid nanoparticle (LPH-NP)] for systemically delivering siRNA into the tumor. The LPH-NP was prepared in a self-assembling process. Briefly, protamine and a mixture of siRNA and hyaluronic acid were mixed to prepare a negatively charged complex. Then, cationic liposomes were added to coat the complex with lipids via charge-charge interaction to prepare the LPH-NP. The LPH-NP was further modified by DSPE-PEG or DSPE-PEG-anisamide by the post-insertion method. Anisamide is a targeting ligand for the sigma receptor over-expressed in the B16F10 melanoma cells. The particle size, zeta potential and siRNA encapsulation efficiency of the formulation were approximately 115 nm, +25 mV and 90%, respectively. Luciferase siRNA was used to evaluate the gene silencing activity in the B16F10 cells, which were stably transduced with a luciferase gene. The targeted LPH-NP (PEGylated with ligand) silenced 80% of luciferase activity in the metastatic B16F10 tumor in the lung after a single i.v. injection (0.15 mg siRNA/kg). The targeted LPH-NP also showed very little immunotoxicity in a wide dose range (0.15 – 1.2 mg siRNA/kg), while the previously published formulation, LPD-NP (liposome-protamine-DNA nanoparticle), had a much narrow therapeutic window (0.15–0.45 mg/kg).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms
Akinc, A., Querbes, W., De, S., Qin, J., Frank-Kamenetsky, M., Jayaprakash, K. N., Jayaraman, M., Rajeev, K. G., Cantley, W. L., Dorkin, J. R., et al. (2010) · Molecular Therapy · doi:10.1038/mt.2010.85 · Cited by 1,261
siRNA versus miRNA as therapeutics for gene silencing
Lam, J. K. W., Chow, M. Y. T., Zhang, Y., & Leung, S. W. S. (2015) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2015.23 · Cited by 1,081
Hatakeyama, H., Akita, H., & Harashima, H. (2011) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2010.09.001 · Cited by 645
Stealth nanoparticles: High density but sheddable PEG is a key for tumor targeting
Li, S.-D., & Huang, L. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.03.016 · Cited by 562
Self-citationOh, E. J., Park, K., Kim, K. S., Kim, J., Yang, J.-A., Kong, J.-H., Lee, M. Y., Hoffman, A. S., & Hahn, S. K. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.09.010 · Cited by 540
Nanoparticles Modified With Tumor-targeting scFv Deliver siRNA and miRNA for Cancer Therapy
Chen, Y., Zhu, X., Zhang, X., Liu, B., & Huang, L. (2010) · Molecular Therapy · doi:10.1038/mt.2010.136 · Cited by 515
Self-citationNanomedicine in pulmonary delivery
Mansour, H., Haemosu, & Wu, X. (2009) · International Journal of Nanomedicine · doi:10.2147/ijn.s4937 · Cited by 485
Biodegradable calcium phosphate nanoparticle with lipid coating for systemic siRNA delivery
Li, J., Chen, Y.-C., Tseng, Y.-C., Mozumdar, S., & Huang, L. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.11.008 · Cited by 470
Self-citationMore Effective Nanomedicines through Particle Design
Wang, J., Byrne, J. D., Napier, M. E., & DeSimone, J. M. (2011) · Small · doi:10.1002/smll.201100442 · Cited by 466
Lipid-based systemic delivery of siRNA
Tseng, Y.-C., Mozumdar, S., & Huang, L. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.003 · Cited by 463
Self-citationThe uptake and intracellular fate of PLGA nanoparticles in epithelial cells
Cartiera, M. S., Johnson, K. M., Rajendran, V., Caplan, M. J., & Saltzman, W. M. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.01.057 · Cited by 412
Cytokines as biomarkers of nanoparticle immunotoxicity
Elsabahy, M., & Wooley, K. L. (2013) · Chemical Society Reviews · doi:10.1039/c3cs60064e · Cited by 407
A review of nanocarriers for the delivery of small interfering RNA
Kesharwani, P., Gajbhiye, V., & Jain, N. K. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.06.068 · Cited by 368
In Vivo Gene Delivery by Nonviral Vectors: Overcoming Hurdles?
Zhang, Y., Satterlee, A., & Huang, L. (2012) · Molecular Therapy · doi:10.1038/mt.2012.79 · Cited by 349
Self-citationConfirming the RNAi-mediated mechanism of action of siRNA-based cancer therapeutics in mice
Judge, A. D., Robbins, M., Tavakoli, I., Levi, J., Hu, L., Fronda, A., Ambegia, E., McClintock, K., & MacLachlan, I. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37515 · Cited by 336
Therapeutic plasmid DNA versus siRNA delivery: Common and different tasks for synthetic carriers
Scholz, C., & Wagner, E. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.11.014 · Cited by 333
Non-viral vectors for RNA delivery
Yan, Y., Liu, X.-Y., Lu, A., Wang, X.-Y., Jiang, L.-X., & Wang, J.-C. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.008 · Cited by 332
Li, J., Yang, Y., & Huang, L. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.10.020 · Cited by 306
Self-citationTheranostic Nanoparticles Engineered for Clinic and Pharmaceutics
Ma, X., Zhao, Y., & Liang, X.-J. (2011) · Accounts of Chemical Research · doi:10.1021/ar2000056 · Cited by 297
Lipid nanoparticles for delivery of RNA therapeutics: Current status and the role of in vivo imaging
Jung, H. N., Lee, S.-Y., Lee, S., Youn, H., & Im, H.-J. (2022) · Theranostics · doi:10.7150/thno.77259 · Cited by 282
Qhattal, H. S. S., & Liu, X. (2011) · Molecular Pharmaceutics · doi:10.1021/mp2000428 · Cited by 254
Nonviral methods for siRNA delivery
Gao, K., & Huang, L. (2009) · Molecular Pharmaceutics · doi:10.1021/mp800134q · Cited by 244
Self-citationTargeting Tumor-Associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors
Miao, L., Liu, Q., Lin, C. M., Luo, C., Wang, Y., Liu, L., Yin, W., Hu, S., Kim, W. Y., & Huang, L. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-0866 · Cited by 215
“GFP-LPD exhibited a slight antitumor effect, likely from the non-specific induction of inflammatory cytokines from the cargos and DNA backbones (24).”
Self-citationLiu, H.-A., Liu, Y.-L., Ma, Z.-Z., Wang, J.-C., & Zhang, Q. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-5891 · Cited by 97
Liposomal gene delivery mediated by tissue-engineered scaffolds
Kulkarni, M., Greiser, U., O’Brien, T., & Pandit, A. (2010) · Trends in Biotechnology · doi:10.1016/j.tibtech.2009.10.003 · Cited by 81
Liang, Y., Peng, J., Li, N., Yu-Wai-Man, C., Wang, Q., Xu, Y., Wang, H., Tagalakis, A. D., & Du, Z. (2019) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2018.09.018 · Cited by 30
“(14) In addition, the lipopolyplexes assembled by liposome/protamine/siRNA(15) and receptor-targeted nanocomplexes (RTNs) designed through modular strategy(16) and inorganic nanocomplexes modified by biomaterials(17) have been reported”
Background
Metadata
- Authors
- Chono, S., Li, S.-D., Conwell, C. C., & Huang, L.
- Venue
- Journal of Controlled Release
- Publisher
- Elsevier BV
- Published
- 2008-10
- Volume
- 131
- Issue
- 1
- Pages
- 64-69
- ISSN
- 0168-3659 (ISSN-L)
- OpenAlex
- W2021218243
- Cited by
- 238
- References
- 0
- FWCI
- 8.56
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.